- Investing Ideas
- U.S. Pharmaceuticals & Biotech Breakout Stocks
U.S. Pharmaceuticals & Biotech Breakout Stocks
Results
22
Stocks where the price continues to rise after more than a year of consistent gains.
22 companies
BioNTech
Market Cap: US$28.3b
Engages in the development and commercialization of immunotherapies in Germany.
BNTX
US$114.05
7D
23.0%
1Y
8.8%
Twist Bioscience
Market Cap: US$8.8b
Manufactures and sells synthetic DNA-based products.
TWST
US$151.42
7D
30.4%
1Y
446.2%
Iovance Biotherapeutics
Market Cap: US$3.7b
A commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.
IOVA
US$8.44
7D
20.1%
1Y
244.5%
Maravai LifeSciences Holdings
Market Cap: US$2.2b
A life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America.
MRVI
US$9.00
7D
56.8%
1Y
271.9%
Personalis
Market Cap: US$1.8b
Develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.
PSNL
US$17.25
7D
24.0%
1Y
253.5%
Inhibrx Biosciences
Market Cap: US$1.5b
A clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.
INBX
US$122.72
7D
29.7%
1Y
373.5%
Immix Biopharma
Market Cap: US$973.7m
A clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia.
IMMX
US$14.47
7D
22.5%
1Y
582.5%
Nuvectis Pharma
Market Cap: US$777.7m
A clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology.
NVCT
US$25.89
7D
23.8%
1Y
278.0%
Entera Bio
Market Cap: US$592.1m
A clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally.
ENTX
US$3.47
7D
20.1%
1Y
75.3%
Prime Medicine
Market Cap: US$578.2m
A biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States.
PRME
US$3.71
7D
21.6%
1Y
2.2%
Pacific Biosciences of California
Market Cap: US$397.9m
Designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.
PACB
US$1.52
7D
33.3%
1Y
15.2%
Compugen
Market Cap: US$245.3m
A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.
CGEN
US$2.87
7D
20.6%
1Y
97.9%
Cypherpunk Technologies
Market Cap: US$181.0m
A privacy technology company, implements a digital asset strategy anchored by Zcash in the United States.
CYPH
US$1.64
7D
103.6%
1Y
453.5%
Rafael Holdings
Market Cap: US$113.9m
Primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel.
RFL
US$2.24
7D
20.4%
1Y
46.4%
RenovoRx
Market Cap: US$56.4m
A clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment.
RNXT
US$1.42
7D
21.4%
1Y
53.7%
Marker Therapeutics
Market Cap: US$25.0m
A clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States.
MRKR
US$1.52
7D
32.2%
1Y
52.0%
BioVie
Market Cap: US$16.1m
A clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States.
BIVI
US$2.09
7D
116.7%
1Y
32.3%
Cardiac Biotech Solutions
Market Cap: US$6.8m
Through its subsidiaries, provides ambulatory non-invasive cardiac monitoring products and services in the United States and internationally.
CBSC
US$0.04
7D
22.4%
1Y
2.6%
Orgenesis
Market Cap: US$5.8m
A biotech company, focuses on cell and gene therapies in the United States.
ORGS
US$0.58
7D
93.3%
1Y
2,536.4%
Eastgate Biotech
Market Cap: US$3.2m
A development stage company, develops novel formulations of natural compounds and pharmaceutical products.
ETBI
US$0.003
7D
500.0%
1Y
0%
Emmaus Life Sciences
Market Cap: US$2.9m
A commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally.
EMMA
US$0.039
7D
254.5%
1Y
230.5%
Cannonau
Market Cap: US$72.5k
Engages in the provision of cannabidiol based products.
CNNC
US$0.0003
7D
50.0%
1Y
200.0%